---
id: asn-hyperkalemia-2024
title: "ASN 2024 Clinical Practice Guideline: Management of Hyperkalemia"
short_title: "ASN Hyperkalemia 2024"

organization: American Society of Nephrology
collaborators: null
country: US
url: https://www.asn-online.org/
doi: null
pmid: null
open_access: true

specialty: nephrology
guideline_type: clinical-practice
evidence_system: ASN
conditions:
  - hyperkalemia
  - potassium disorders
  - electrolyte abnormality
tags:
  - calcium gluconate
  - insulin
  - patiromer
  - dialysis
  - sodium zirconium cyclosilicate

publication_date: 2024-06-01
previous_version_date: null
status: current
supersedes: null
superseded_by: null

pdf_path: null
has_pdf: false
last_reviewed: 2025-12-26
---

## Scope
2024 ASN clinical practice guideline on the recognition and management of hyperkalemia.

## Key Recommendations

### Definition
- Mild: 5.0-5.9 mEq/L.
- Moderate: 6.0-6.4 mEq/L.
- Severe: â‰¥6.5 mEq/L.
- Confirm true hyperkalemia (rule out pseudohyperkalemia from hemolysis).

### ECG Findings (Variable and Unreliable)
- Peaked T waves, PR prolongation, QRS widening, sine wave pattern, ventricular arrhythmias.
- ECG changes may occur at any level; absence does not exclude serious hyperkalemia.

### Acute Management (Moderate-Severe or Symptomatic)

#### Membrane Stabilization
- **Calcium Gluconate 10%**: 10-20 mL IV over 2-3 minutes. Cardioprotective; does not lower potassium. Repeat if ongoing ECG changes.
- Use calcium chloride via central line if gluconate unavailable.

#### Shift Potassium Into Cells
- **Insulin + Glucose**: Regular insulin 10 units IV + dextrose 25-50 g IV (to prevent hypoglycemia). Onset ~15-30 min, duration 2-4 hours.
- **Albuterol (Nebulized)**: 10-20 mg. Additive effect with insulin.
- **Sodium Bicarbonate**: Less effective acutely; consider in metabolic acidosis.

#### Remove Potassium from Body
- **Loop Diuretics (Furosemide)**: If adequate renal function.
- **Potassium Binders**:
  - **Sodium Polystyrene Sulfonate (Kayexalate)**: Limited role acutely; slow onset.
  - **Patiromer (Veltassa)**: Non-acute setting; maintenance therapy.
  - **Sodium Zirconium Cyclosilicate (Lokelma)**: Faster onset; may be used acutely.
- **Hemodialysis**: Definitive removal for severe/refractory hyperkalemia or renal failure.

### Chronic Management
- Dietary potassium restriction.
- Reduce/modify RAAS inhibitors if safe.
- Potassium binders (patiromer, SZC) to enable continued RAAS inhibitor use in CKD/HF.
